<p><strong><em>通过集成软件、服务和人工智能驱动增长</em></strong></p>
<p>北卡罗来纳州研究三角园区 --（商业资讯）--Simulations Plus, Inc.（纳斯达克：SLP）（“Simulations Plus” 或 “公司”），全球领先的基于模型和人工智能加速的药物开发公司，推动生物制药创新，今天宣布将于 2026 年 1 月 21 日（星期三）举办虚拟投资者日活动。</p>
<p>此次活动将为投资者和分析师提供深入了解公司长期战略、产品路线图和财务展望的机会，并将有公司高管团队的问答环节。</p>
<p>“生物制药公司正在重新思考如何开发药物——在每一步中优先考虑更大的可预测性、透明度和科学严谨性。Simulations Plus 正好处于这些需求的交汇点，” Simulations Plus 首席执行官 Shawn O’Connor 表示。“我们致力于帮助客户以清晰和自信的方式应对这种复杂性。在投资者日活动中，我们将展示我们的统一战略如何使我们能够支持药物开发的下一个创新时代。”</p>
<p>与会者将深入了解 Simulations Plus 对集成的、人工智能驱动的建模生态系统的愿景，该生态系统涵盖发现、开发、临床运营和商业化。议程将包括以下内容的更新：</p>
<ul>
<li>行业环境及模型驱动药物开发（MIDD）的加速采用</li>
<li>公司的统一产品和技术战略</li>
<li>支持客户在药物生命周期中工作流程的科学服务进展</li>
<li>财务优先事项和展望</li>
</ul>
<p>此次活动将进行现场直播，活动结束后将发布重播。</p>
<p><strong>活动详情</strong></p>
<ul>
<li>** 日期：**2026 年 1 月 21 日，星期三</li>
<li><strong>时间：</strong> 东部时间下午 1:00 – 下午 2:30</li>
<li><strong>地点：</strong> 虚拟</li>
<li><strong>网络直播注册：</strong> 点击这里</li>
</ul>
<p><strong>关于 Simulations Plus, Inc.</strong></p>
<p>Simulations Plus 是全球领先的基于模型和人工智能加速的药物开发公司。我们通过创新的基于科学的软件和咨询解决方案，为客户加速药物及其他产品的发现、开发和商业化创造价值。欲了解更多信息，请访问 www.simulations-plus.com。</p>
<p><strong>环境、社会和治理</strong></p>
<p>我们将环境、社会和治理（ESG）工作的重点放在我们能够产生最大积极影响的地方。要了解我们最新的倡议和优先事项，请访问我们的网站。</p>
<p><strong>前瞻性声明</strong></p>
<p>除历史信息外，本新闻稿中讨论的事项均为前瞻性声明，涉及风险和不确定性。诸如 “相信”、“将”、“可以”、“期待”、“预期” 等词语（或这些术语的否定形式，以及其他引用未来事件、条件或情况的词语或表达）意味着这些是我们在撰写时的最佳估计，但不能保证预期或预期的结果或事件实际上会发生，因此我们的实际未来结果可能与这些声明有显著差异。这些前瞻性声明基于当前的假设和预期，涉及可能导致实际结果与所表达或暗示的结果有实质性差异的风险和不确定性。可能导致或促成这种差异的因素包括但不限于：我们新的内部运营结构的有效性、我们维持竞争优势和商业化人工智能及云解决方案的能力、监管和数据隐私标准的演变、客户对新软件及现有软件改进版本的接受程度、制药行业的整体经济状况、我们融资增长的能力、我们继续吸引和留住高素质技术人员的能力、市场条件、宏观经济因素和可持续市场。有关我们风险因素的更多信息，请参阅我们向美国证券交易委员会提交的季度、年度和当前报告。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg4Njc3NjFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg4Njc3NjFyMQ"/></p>
<p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20251218867761/en/</p>
<p><strong>投资者关系联系人</strong>：</p>
<p>Lisa Fortuna</p>
<p>Financial Profiles</p>
<p>310-622-8251</p>
<p>slp@finprofiles.com</p>
<p>来源：Simulations Plus, Inc.</p>

<p>Simulations Plus, Inc. 将于 2026 年 1 月 21 日举办一次虚拟投资者日活动，展示其基于模型的药物开发战略。此次活动将涵盖公司的长期战略、产品路线图和财务展望，并提供其人工智能驱动的建模生态系统的见解。网络直播将包括行业趋势、产品战略、科学服务和财务优先事项的更新。此次活动旨在展示 Simulations Plus 如何支持药物开发中的创新</p>

<p><strong><em>Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem</em></strong></p>
<div class="lb-trans"><p><strong><em>通过集成软件、服务和人工智能驱动增长</em></strong></p>
</div><p>RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will host a virtual Investor Day on Wednesday, January 21, 2026.</p>
<div class="lb-trans"><p>北卡罗来纳州研究三角园区 --（商业资讯）--Simulations Plus, Inc.（纳斯达克：SLP）（“Simulations Plus” 或 “公司”），全球领先的基于模型和人工智能加速的药物开发公司，推动生物制药创新，今天宣布将于 2026 年 1 月 21 日（星期三）举办虚拟投资者日活动。</p>
</div><p>The event will offer investors and analysts an in-depth look at the Company’s long-term strategy, product roadmap, and financial outlook, as well as a Q&amp;A session with the executive leadership team.</p>
<div class="lb-trans"><p>此次活动将为投资者和分析师提供深入了解公司长期战略、产品路线图和财务展望的机会，并将有公司高管团队的问答环节。</p>
</div><p>“Biopharma companies are rethinking how they develop medicines—prioritizing greater predictability, transparency, and scientific rigor at every step. Simulations Plus sits at the intersection of these needs,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “We are committed to helping our clients navigate this complexity with clarity and confidence. During Investor Day, we will demonstrate how our unified strategy positions us to support the next era of innovation in drug development.”</p>
<div class="lb-trans"><p>“生物制药公司正在重新思考如何开发药物——在每一步中优先考虑更大的可预测性、透明度和科学严谨性。Simulations Plus 正好处于这些需求的交汇点，” Simulations Plus 首席执行官 Shawn O’Connor 表示。“我们致力于帮助客户以清晰和自信的方式应对这种复杂性。在投资者日活动中，我们将展示我们的统一战略如何使我们能够支持药物开发的下一个创新时代。”</p>
</div><p>Attendees will gain insight into Simulations Plus’ vision for an integrated, AI-enabled modeling ecosystem spanning discovery, development, clinical operations, and commercialization. The agenda will include updates on:</p>
<div class="lb-trans"><p>与会者将深入了解 Simulations Plus 对集成的、人工智能驱动的建模生态系统的愿景，该生态系统涵盖发现、开发、临床运营和商业化。议程将包括以下内容的更新：</p>
</div><ul>
<li>The industry environment and the accelerating adoption of model-informed drug development (MIDD)</li>
<li>The Company’s unified product and technology strategy</li>
<li>Advances in scientific services supporting client workflows across the drug lifecycle</li>
<li>Financial priorities and outlook</li>
</ul>
<div class="lb-trans"><ul>
<li>行业环境及模型驱动药物开发（MIDD）的加速采用</li>
<li>公司的统一产品和技术战略</li>
<li>支持客户在药物生命周期中工作流程的科学服务进展</li>
<li>财务优先事项和展望</li>
</ul>
</div><p>The event will be webcast live, and a replay will be posted following the event.</p>
<div class="lb-trans"><p>此次活动将进行现场直播，活动结束后将发布重播。</p>
</div><p><strong>Event Details</strong></p>
<div class="lb-trans"><p><strong>活动详情</strong></p>
</div><ul>
<li><strong>Date:</strong> Wednesday, January 21, 2026</li>
<li><strong>Time:</strong> 1:00 PM ET – 2:30 PM ET</li>
<li><strong>Location:</strong> Virtual</li>
<li><strong>Webcast Registration:</strong> Here</li>
</ul>
<div class="lb-trans"><ul>
<li>** 日期：**2026 年 1 月 21 日，星期三</li>
<li><strong>时间：</strong> 东部时间下午 1:00 – 下午 2:30</li>
<li><strong>地点：</strong> 虚拟</li>
<li><strong>网络直播注册：</strong> 点击这里</li>
</ul>
</div><p><strong>About Simulations Plus, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Simulations Plus, Inc.</strong></p>
</div><p>Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com.</p>
<div class="lb-trans"><p>Simulations Plus 是全球领先的基于模型和人工智能加速的药物开发公司。我们通过创新的基于科学的软件和咨询解决方案，为客户加速药物及其他产品的发现、开发和商业化创造价值。欲了解更多信息，请访问 www.simulations-plus.com。</p>
</div><p><strong>Environmental, Social, and Governance</strong></p>
<div class="lb-trans"><p><strong>环境、社会和治理</strong></p>
</div><p>We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website.</p>
<div class="lb-trans"><p>我们将环境、社会和治理（ESG）工作的重点放在我们能够产生最大积极影响的地方。要了解我们最新的倡议和优先事项，请访问我们的网站。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “believe”, “expect,” “anticipate” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.</p>
<div class="lb-trans"><p>除历史信息外，本新闻稿中讨论的事项均为前瞻性声明，涉及风险和不确定性。诸如 “相信”、“将”、“可以”、“期待”、“预期” 等词语（或这些术语的否定形式，以及其他引用未来事件、条件或情况的词语或表达）意味着这些是我们在撰写时的最佳估计，但不能保证预期或预期的结果或事件实际上会发生，因此我们的实际未来结果可能与这些声明有显著差异。这些前瞻性声明基于当前的假设和预期，涉及可能导致实际结果与所表达或暗示的结果有实质性差异的风险和不确定性。可能导致或促成这种差异的因素包括但不限于：我们新的内部运营结构的有效性、我们维持竞争优势和商业化人工智能及云解决方案的能力、监管和数据隐私标准的演变、客户对新软件及现有软件改进版本的接受程度、制药行业的整体经济状况、我们融资增长的能力、我们继续吸引和留住高素质技术人员的能力、市场条件、宏观经济因素和可持续市场。有关我们风险因素的更多信息，请参阅我们向美国证券交易委员会提交的季度、年度和当前报告。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg4Njc3NjFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251218867761r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251218867761/en/</p>
<div class="lb-trans"><p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20251218867761/en/</p>
</div><p><strong>Investor Relations Contact</strong>:</p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong>：</p>
</div><p>Lisa Fortuna</p>
<div class="lb-trans"><p>Lisa Fortuna</p>
</div><p>Financial Profiles</p>
<div class="lb-trans"><p>Financial Profiles</p>
</div><p>310-622-8251</p>
<div class="lb-trans"><p>310-622-8251</p>
</div><p>slp@finprofiles.com</p>
<div class="lb-trans"><p>slp@finprofiles.com</p>
</div><p>Source: Simulations Plus, Inc.</p>
<div class="lb-trans"><p>来源：Simulations Plus, Inc.</p>
</div>

Simulations Plus 将举办虚拟投资者日，重点介绍下一时代模型驱动药物开发的战略 | SLP 股票新闻